Snell & Wilmer has advised Traws Pharma, Inc. Traws Pharma, Inc. (Nasdaq: TRAW), a clinical-stage biopharmaceutical company, has entered into a securities purchase agreement with new...
Traws Pharma Secures Up to $60 Million in Private Placement Financing
Tivic Health Secures $90M+ Funding and Acquires Manufacturing Assets from Scorpius Holdings
Snell & Wilmer has advised Tivic Health Systems, Inc. Tivic Health Systems, Inc. (Nasdaq:TIVC), a diversified therapeutics company focused on immune-based treatments, has completed the acquisition...
Barinthus Biotherapeutics and Clywedog Therapeutics Announce All-Stock Merger to Advance Metabolic and Autoimmune Disease Treatments
Goodwin Procter has advised Barinthus Biotherapeutics, and Snell & Wilmer has advised Clywedog Therapeutics. Barinthus Biotherapeutics plc and Clywedog Therapeutics, Inc. have entered into a definitive...
Lomond Therapeutics’ $20 Million Private Investment Financing
Snell & Wilmer represented Lomond Therapeutics Holdings, Inc. in the transaction. Lomond Therapeutics Holdings, Inc. (“Lomond Therapeutics”), a clinical-stage biotechnology company, announced the addition of two...